<p><strong>Aytu BioPharma, Inc.</strong> (NASDAQ:AYTU) 的股票在經歷了一段動盪期後，最近一個月表現非常出色，漲幅達 28%。回顧更長時間，令人鼓舞的是，該股票在過去一年中上漲了 85%。</p>
<p>即使在如此大幅的價格跳升之後，考慮到美國製藥行業幾乎一半的公司市銷率（&#34;P/S&#34;）超過 4.3 倍，甚至有些超過 25 倍，Aytu BioPharma 目前仍可能被視為一個強勁的買入機會，其市銷率為 0.4 倍。不過，僅僅根據市銷率來判斷並不明智，因為可能有解釋説明其如此低的原因。</p>
<p>這項技術可能會取代計算機：發現 20 只正在努力使量子計算成為現實的股票。</p>
<p>查看我們對 Aytu BioPharma 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/291629081-ps-multiple-vs-industry-1-dark-2/1766237641895?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/291629081-ps-multiple-vs-industry-1-dark-2/1766237641895"/></p>
<p>NasdaqCM:AYTU 市銷率與行業比較 2025 年 12 月 20 日</p>
<h3>Aytu BioPharma 最近的表現如何？</h3>
<p>Aytu BioPharma 最近的表現不佳，其收入下降與其他公司相比顯得相形見絀，後者的收入平均有所增長。似乎許多人預期收入表現不佳將持續，這抑制了市銷率。如果你仍然喜歡這家公司，你會希望這種情況並非如此，以便在它不受歡迎時能夠買入一些股票。</p>
<p>如果你想了解分析師對未來的預測，可以查看我們對 Aytu BioPharma 的 <strong>免費</strong> 報告。</p>
<h2>Aytu BioPharma 是否有收入增長的預測？</h2>
<p>為了證明其市銷率的合理性，Aytu BioPharma 需要實現微弱的增長，且增長幅度顯著低於行業水平。</p>
<p>回顧過去一年，該公司的收入幾乎與前一年持平。這並不是股東所期待的，因為這意味着他們在過去三年中總共經歷了 38% 的收入下降。因此，可以公平地説，最近的收入增長對公司來説並不理想。</p>
<p>展望未來，覆蓋該公司的三位分析師的估計表明，收入增長將進入負增長領域，預計在未來一年下降 2.9%。這並不理想，而行業其他部分預計將增長 25%。</p>
<p>鑑於此，Aytu BioPharma 的市銷率低於大多數其他公司是可以理解的。然而，收入的萎縮不太可能在長期內導致穩定的市銷率。即使只是維持這些價格，在疲軟的前景下也可能難以實現。</p>
<h2>我們可以從 Aytu BioPharma 的市銷率中學到什麼？</h2>
<p>即使在如此強勁的價格波動之後，Aytu BioPharma 的市銷率仍然落後於行業其他公司。通常情況下，我們會警惕在做出投資決策時過度解讀市銷率，儘管它可以揭示其他市場參與者對公司的看法。</p>
<p>顯然，Aytu BioPharma 因其收入下滑的預測而維持低市銷率。在這一階段，投資者認為收入改善的潛力不足以證明更高的市銷率。在這種情況下，很難看到股價在不久的將來強勁上漲。</p>
<p>還有其他重要的風險因素需要考慮，我們發現了 <strong>Aytu BioPharma 的 3 個警示信號</strong>（其中 1 個讓我們有些不安！），在投資之前你應該瞭解這些。</p>
<p>如果這些 <strong>風險讓你重新考慮對 Aytu BioPharma 的看法</strong>，可以探索我們互動的高質量股票列表，以瞭解還有什麼其他選擇。</p>
<p>用於國防和災難的移動基礎設施</p>
<p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨處可用。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

AYTU

<p>Aytu BioPharma, Inc.（納斯達克代碼：AYTU）的股票最近上漲了 28%，在過去一年中上漲了 85%。儘管如此，其市銷率為 0.4 倍，低於行業平均水平。該公司的收入在三年內下降了 38%，分析師預測明年的收入將下降 2.9%，而行業則預計增長 25%。這種疲軟的前景使其市銷率保持在低位，暗示股價增長的潛力有限</p>

<p><strong>Aytu BioPharma, Inc.</strong> (NASDAQ:AYTU) shares have had a really impressive month, gaining 28% after a shaky period beforehand. Looking back a bit further, it's encouraging to see the stock is up 85% in the last year.</p>
<div class="lb-trans"><p><strong>Aytu BioPharma, Inc.</strong> (NASDAQ:AYTU) 的股票在經歷了一段動盪期後，最近一個月表現非常出色，漲幅達 28%。回顧更長時間，令人鼓舞的是，該股票在過去一年中上漲了 85%。</p>
</div><p>Even after such a large jump in price, Aytu BioPharma may still look like a strong buying opportunity at present with its price-to-sales (or &#34;P/S&#34;) ratio of 0.4x, considering almost half of all companies in the Pharmaceuticals industry in the United States have P/S ratios greater than 4.3x and even P/S higher than 25x aren't out of the ordinary. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so limited.</p>
<div class="lb-trans"><p>即使在如此大幅的價格跳升之後，考慮到美國製藥行業幾乎一半的公司市銷率（&#34;P/S&#34;）超過 4.3 倍，甚至有些超過 25 倍，Aytu BioPharma 目前仍可能被視為一個強勁的買入機會，其市銷率為 0.4 倍。不過，僅僅根據市銷率來判斷並不明智，因為可能有解釋説明其如此低的原因。</p>
</div><p>This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.</p>
<div class="lb-trans"><p>這項技術可能會取代計算機：發現 20 只正在努力使量子計算成為現實的股票。</p>
</div><p>Check out our latest analysis for Aytu BioPharma</p>
<div class="lb-trans"><p>查看我們對 Aytu BioPharma 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/291629081-ps-multiple-vs-industry-1-dark-2/1766237641895" alt="" original-src="https://images.simplywall.st/asset/chart/291629081-ps-multiple-vs-industry-1-dark-2/1766237641895"/></p>
<p>NasdaqCM:AYTU Price to Sales Ratio vs Industry December 20th 2025</p>
<div class="lb-trans"><p>NasdaqCM:AYTU 市銷率與行業比較 2025 年 12 月 20 日</p>
</div><h3>How Has Aytu BioPharma Performed Recently?</h3>
<div class="lb-trans"><h3>Aytu BioPharma 最近的表現如何？</h3>
</div><p>Aytu BioPharma hasn't been tracking well recently as its declining revenue compares poorly to other companies, which have seen some growth in their revenues on average. It seems that many are expecting the poor revenue performance to persist, which has repressed the P/S ratio. If you still like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>Aytu BioPharma 最近的表現不佳，其收入下降與其他公司相比顯得相形見絀，後者的收入平均有所增長。似乎許多人預期收入表現不佳將持續，這抑制了市銷率。如果你仍然喜歡這家公司，你會希望這種情況並非如此，以便在它不受歡迎時能夠買入一些股票。</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on Aytu BioPharma.</p>
<div class="lb-trans"><p>如果你想了解分析師對未來的預測，可以查看我們對 Aytu BioPharma 的 <strong>免費</strong> 報告。</p>
</div><h2>Is There Any Revenue Growth Forecasted For Aytu BioPharma?</h2>
<div class="lb-trans"><h2>Aytu BioPharma 是否有收入增長的預測？</h2>
</div><p>In order to justify its P/S ratio, Aytu BioPharma would need to produce anemic growth that's substantially trailing the industry.</p>
<div class="lb-trans"><p>為了證明其市銷率的合理性，Aytu BioPharma 需要實現微弱的增長，且增長幅度顯著低於行業水平。</p>
</div><p>Retrospectively, the last year delivered virtually the same number to the company's top line as the year before. This isn't what shareholders were looking for as it means they've been left with a 38% decline in revenue over the last three years in total. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.</p>
<div class="lb-trans"><p>回顧過去一年，該公司的收入幾乎與前一年持平。這並不是股東所期待的，因為這意味着他們在過去三年中總共經歷了 38% 的收入下降。因此，可以公平地説，最近的收入增長對公司來説並不理想。</p>
</div><p>Shifting to the future, estimates from the three analysts covering the company suggest revenue growth is heading into negative territory, declining 2.9% over the next year. That's not great when the rest of the industry is expected to grow by 25%.</p>
<div class="lb-trans"><p>展望未來，覆蓋該公司的三位分析師的估計表明，收入增長將進入負增長領域，預計在未來一年下降 2.9%。這並不理想，而行業其他部分預計將增長 25%。</p>
</div><p>In light of this, it's understandable that Aytu BioPharma's P/S would sit below the majority of other companies. However, shrinking revenues are unlikely to lead to a stable P/S over the longer term. Even just maintaining these prices could be difficult to achieve as the weak outlook is weighing down the shares.</p>
<div class="lb-trans"><p>鑑於此，Aytu BioPharma 的市銷率低於大多數其他公司是可以理解的。然而，收入的萎縮不太可能在長期內導致穩定的市銷率。即使只是維持這些價格，在疲軟的前景下也可能難以實現。</p>
</div><h2>What We Can Learn From Aytu BioPharma's P/S?</h2>
<div class="lb-trans"><h2>我們可以從 Aytu BioPharma 的市銷率中學到什麼？</h2>
</div><p>Even after such a strong price move, Aytu BioPharma's P/S still trails the rest of the industry. Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.</p>
<div class="lb-trans"><p>即使在如此強勁的價格波動之後，Aytu BioPharma 的市銷率仍然落後於行業其他公司。通常情況下，我們會警惕在做出投資決策時過度解讀市銷率，儘管它可以揭示其他市場參與者對公司的看法。</p>
</div><p>It's clear to see that Aytu BioPharma maintains its low P/S on the weakness of its forecast for sliding revenue, as expected. At this stage investors feel the potential for an improvement in revenue isn't great enough to justify a higher P/S ratio. It's hard to see the share price rising strongly in the near future under these circumstances.</p>
<div class="lb-trans"><p>顯然，Aytu BioPharma 因其收入下滑的預測而維持低市銷率。在這一階段，投資者認為收入改善的潛力不足以證明更高的市銷率。在這種情況下，很難看到股價在不久的將來強勁上漲。</p>
</div><p>There are also other vital risk factors to consider and we've discovered <strong>3 warning signs for Aytu BioPharma</strong> (1 makes us a bit uncomfortable!) that you should be aware of before investing here.</p>
<div class="lb-trans"><p>還有其他重要的風險因素需要考慮，我們發現了 <strong>Aytu BioPharma 的 3 個警示信號</strong>（其中 1 個讓我們有些不安！），在投資之前你應該瞭解這些。</p>
</div><p>If these <strong>risks are making you reconsider your opinion on Aytu BioPharma</strong>, explore our interactive list of high quality stocks to get an idea of what else is out there.</p>
<div class="lb-trans"><p>如果這些 <strong>風險讓你重新考慮對 Aytu BioPharma 的看法</strong>，可以探索我們互動的高質量股票列表，以瞭解還有什麼其他選擇。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用於國防和災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨處可用。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

Aytu BioPharma, Inc. (NASDAQ:AYTU) 的股票上漲了 28%，但其股價和業務表現仍然落後於行業水平